- Page 1 and 2: CHANGES IN PROTEIN PROFILES IN BORT
- Page 3 and 4: ACKNOWLEDGEMENTS First of all, with
- Page 5 and 6: ÖZET BORTEZOMĠB UYGULANAN MULTĠP
- Page 7 and 8: 2.1.4.1.2. Two-Dimensional Gel Elec
- Page 9: LIST OF FIGURES Figure Page Figure
- Page 13 and 14: When normal cells in the body begin
- Page 15 and 16: Figure 1.2. Development of Cancer S
- Page 17 and 18: the myeloma cells does not help fig
- Page 19 and 20: A rare form of MM called Nonsecreto
- Page 21 and 22: 1.2.3. Risk Factors for MM A risk f
- Page 23 and 24: of the mineralizations by adjusting
- Page 25 and 26: To measure the levels of red cells,
- Page 27 and 28: The levels of blood urea nitrogen (
- Page 29 and 30: By using the system introduced by D
- Page 31 and 32: 1.2.7.2. Biology of The Proteasome
- Page 33 and 34: Figure 1.10. Ubiquitin-Proteasome P
- Page 35 and 36: Figure 1.12. Effect of Bortezomib o
- Page 37 and 38: encompasses the investigation of pr
- Page 39 and 40: of modification. Ubiquitin is a sma
- Page 41 and 42: the given cells. On the other hand,
- Page 43 and 44: is-acrylamide (N,N'-methylene-bisac
- Page 45 and 46: 2.1.4.2. Detection of Protein Spots
- Page 47 and 48: ange of 600-2500 Da. This is the id
- Page 49 and 50: ions resolved by the mass analyzer
- Page 51 and 52: 2.1.4.5.2. Mass Analyzers Figure 2.
- Page 53 and 54: There is no doubt that different ma
- Page 55 and 56: mask low-quantity proteins that may
- Page 57 and 58: 3.1. Materials 3.1.1. Medias CHAPTE
- Page 59 and 60: 3.2.5. Cell Proliferation Assay Ant
- Page 61 and 62:
After 72 hour incubation period at
- Page 63 and 64:
eceptors of the Tumor Necrosis Fact
- Page 65 and 66:
The preparation of stock BSA Standa
- Page 67 and 68:
3.2.6.3. Detection of the Loss of M
- Page 69 and 70:
centrifugation, the supernatant was
- Page 71 and 72:
selected symmetrically to load the
- Page 73 and 74:
approximately 35 ml, the volume of
- Page 75 and 76:
After electrophoresis was finished,
- Page 77 and 78:
7 Day Two: Reduction, Alkylation, a
- Page 79 and 80:
CHAPTER 4 RESULTS AND DISCUSSION 4.
- Page 81 and 82:
% Changes in Cytoplasmic/Mitochondr
- Page 83 and 84:
Table 4.1. Magnified Segments of Di
- Page 85 and 86:
Table 4.1. Magnified Segments of Di
- Page 87 and 88:
After labeling, black and red color
- Page 89 and 90:
78 7 8 Y2S Y3S Table 4.2. Results o
- Page 91 and 92:
80 12 S4Ca Table 4.2. Results of Di
- Page 93 and 94:
82 27 Y5S Table 4.2. Results of Dif
- Page 95 and 96:
Spot 4, Ubiquitin-conjugating enzym
- Page 97 and 98:
is a transcriptional repressor, but
- Page 99 and 100:
activity and loss of mitochondrial
- Page 101 and 102:
distributed, but correlate with nat
- Page 103 and 104:
DeMartino, G. N. and Slaughter, C.
- Page 105 and 106:
proteomic analyses of a systematica
- Page 107 and 108:
Mahindraa, A., Hideshimab, T. and A
- Page 109 and 110:
Richardson, P. G., Hideshima, T. an
- Page 111 and 112:
Terpos, E. 2008. Bortezomib Directl
- Page 113 and 114:
A.1. RPMI-1640 Growth Medium APPEND
- Page 115 and 116:
Table B.1. Chemicals and Reagents U
- Page 117 and 118:
B.4.3. Standard Curve for BSA Table
- Page 119 and 120:
Urea (8M) 4.8 g CHAPS (%2) 0.2 g DT
- Page 121 and 122:
E. F. G. STOCK REAGENT PREPARATION